Assessing the market for a Parkinson’s Disease Technology

Accelerate Associates has completed a market assessment for a Parkinson’s Disease technology on behalf of Leeds Beckett University.

Parkinson’ s disease (PD) is one of the most common neurological conditions. Parkinson’s patients may display shaking which usually begins in the hand or arm and often occurs when the limb is at rest.

Current PD patient assessment relies on the subjective application of clinical criteria. Leeds Beckett University, supported by Grow MedTech, are working on the development of a glove-based sensor technology for patients to use at home. The device will support clinicians in the management of PD and provide reassurance for both patients and their caregivers.

The brief- market assessment for a Parkinson’s Disease technology

Leeds Beckett University required a market assessment of the potential market for the technology. Accelerate Associates helped the team at Leeds Beckett University develop a greater understanding of current techniques and devices employed in the diagnosis and monitoring of Parkinson’s disease. Assessing the market also helped to identify competing technologies and potential barriers to entry.

By undertaking primary research with clinical specialities involved in the treatment of PD patients, the team at Accelerate was able to critique the relative strengths and weaknesses of the Leeds Beckett device and identify potential advantages of the adoption of the clasp glove technology into the NHS.

Assessing the market also required desk research which was used to estimate the size of the market by application i.e., home use, primary care and drug development trials.

Testimonial

“The market assessment carried out by Accelerate Associates has been invaluable for our project team when demonstrating the commercial potential of the technology and acquiring follow-on funding. In particular the interviews carried out with healthcare professionals exceeded expectations and have given us insight into the current care pathway and where our technology could help.”

Share:

Get the latest Accelerate news

Subscribe to our newsletter to receive an e-mail every now and again with all the latest Accelerate news.